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Breast carcinoma remains the most prevalent cancer among 
women, with over 300 000 deaths annually worldwide.[1] According 
to the National Cancer Registry of South Africa (SA), the fre­
quency of histologically diagnosed cases of breast carcinoma in 
SA for 2008 (latest available figures) is 5 923 women and 146 men 
per annum.
Axillary lymph node status is essential for the clinical staging of 
breast carcinoma and remains the single most important predictor of 
disease­free survival in breast carcinoma.[1­3] Only 20 ­ 30% of node­
negative patients will develop recurrence within 10 years, compared 
with about 70% of patients with axillary node involvement.[4,5] It is 
postulated that the sentinel lymph node (SLN) is the first lymph 
node to receive lymphatic drainage from a tumour and is therefore 
the node most likely to contain metastatic disease.[6] A tumour­free 
SLN virtually excludes lymphatic involvement of the entire regional 
lymphatic basin.[4] 
Tumour size is one of the most powerful predictors of tumour 
behaviour in breast cancer.[4] The frequency of nodal metastases in 
patients with tumours smaller than 10 mm is 10 ­ 20%.[4]
SLN biopsy has emerged as a potential alternative to axillary dissec­
tion for staging of breast carcinoma.[6,7] The technique is sensitive 
and specific to predict the axillary lymph node status.[6,7] SLN biopsy 
without axillary dissection is beneficial because it may reduce the 
morbidity associated with axillary dissection.[4] The reported false­
negative rates in the histological examination of SLNs range from 0% 
in smaller, single institution studies to 11.4 % (range 0 ­ 28.6%) in a 
large multi­institution study.[4]
Several recommendations pertaining to techniques for the 
histopathological assessment of an SLN have been published, but a 
standardised and internationally accepted protocol remains contro­
versial.[6,7] Without clear guidelines, sampling and preparation of 
histological slides may be inconsistent. The histological detection 
of micrometastases and single tumour cells requires skill and can be 
missed by an inexperienced pathologist.[3] Immunohistochemistry 
(IHC) has improved the detection of micrometastases and single 
tumour cells.[1,6] Current acceptable standards of practice include 
intraoperative frozen sections of SLN for the detection of metastatic 
breast carcinoma.[6,7] Intraoperative frozen section offers the advantage 
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Objective. To determine effective histological examination of sentinel lymph node (SLN) sections for the detection of metastatic breast 
carcinoma.
Methods. A prospective hospital­based study was done, including 20 patients with confirmed infiltrating breast carcinoma who underwent 
tumour excision or simple mastectomy as well as SLN biopsies. All the lymph nodes harvested were sectioned and embedded. Three sets of 
15 consecutive serial sections were prepared from each case at one sitting, each measuring 3 ­ 5 µm in thickness and mounted on separate 
slides. Each set of 15 consecutive sections was grouped into three levels, each comprising 5 serial sections. The first 4 sections were stained 
with haematoxylin and eosin (H&E). The fifth section was stained for pancytokeratins, using MNF116.
Results. Twenty patients who met the inclusion criteria of this study underwent SLN biopsies and simple mastectomies or tumour excisions. 
Twelve SLNs of 11 patients contained metastatic carcinoma, all detected at level I, with one case requiring MNF116 immunohistochemistry 
staining, revealing metastatic carcinoma, measuring 0.08 × 0.08 mm (micrometastases). The size of metastatic carcinoma ranged between 
0.08 × 0.08 mm (micrometastases) and 25 × 15 mm. Nine cases showed macrometastases, varying in size between 2 × 3.5 mm and 25 
× 15 mm. Tumour sections of three patients with infiltrating carcinoma, of no specific type (NST), revealed lymphovascular invasion. 
The breast tumour sizes of these cases measured 40 × 25 mm (1/1 node involved), 30 × 20 mm (1/3 nodes involved) and 15 × 12 mm 
(1/1 node involved), respectively. Nine patients (19 nodes in total, mean 2.1, range 1 ­ 5) did not have demonstrable metastatic disease in 
the 45 sections of levels I ­ IX, including MNF116 on every fifth section. Patients with negative SLNs varied in age between 29 and 68 years 
and had breast tumour sizes ranging between 10 × 10 mm and 30 × 30 mm, respectively.
Conclusion. This study supports a conservative and cost­effective approach that comprises embedding of the entire SLN and the 
histopathological examination of four H&E­stained sections, which will usually demonstrate metastatic carcinoma. In the event of 
absence of metastatic carcinoma, immunohistochemical staining for pancytokeratin will detect tumour cells in a small percentage of cases. 
Examination of additional H&E­ or pancytokeratin­stained sections is not cost effective. This finding can guide decisions pertaining to 
protocols for the histopathological assessment of SLN in breast carcinoma especially in resource­limited settings.
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of an immediate result that can guide further intraoperative 
management and avoid the need for a second procedure at a later 
stage. However, intraoperative frozen section may be false­negative 
in up to 25% of cases because of suboptimal morphology and 
potential failure to demonstrate the subcapsular region of the lymph 
node.[4] Furthermore, micrometastases may be lost in the unexamined 
tissue subsequent to processing and embedding of the frozen 
tissue. [6] In view of these limitations of intraoperative frozen sections, 
generally accepted practice requires at least three haematoxylin and 
eosin (H&E)­stained tissue sections as well as at least one section 
for pancytokeratin IHC stain.[6,7] This approach is feasible without 
incurring exorbitant costs.[6,7] Significant resource implications of the 
increasing use of the SLN biopsy technique require cost­effective and 
accurate protocols for the histological examination of the SLN for 
detection of metastatic carcinoma.[6,7]
The American Society of Clinical Oncology (ASCO) guideline 
recommends that all submitted nodes be counted, measured and 
cut into perimeridianal (longitudinal) full cross­sections, no thicker 
than 2 mm and stained with H&E for histological assessment.[7] 
Micrometastases will be detected in more instances with serial deeper 
levels than with fewer sections from the surface of the wax block only. 
IHC analysis with antibodies to cytokeratins (MNF116) facilitates the 
detection of isolated tumour deposits.[7]
The objective of this study was to determine effective histological 
examination of SLN sections for the detection of metastatic breast 
carcinoma in a tertiary hospital setting with limited resources. 
From these results, the goal was to establish a protocol for the 
histological examination of SLNs in breast carcinoma and enhance 
the management of patients through increased accuracy of detection 
of metastatic breast carcinoma in SLN biopsies. The outcome will 
facilitate optimisation of protocols for SLN assessment in resource­
limited environments.
Methods
A prospective hospital­based study was done at Tygerberg Hospital, 
Cape Town, SA, during the period 1 June 2014 ­ 31 August 2014. 
The study included 20 patients with confirmed infiltrating breast 
carcinoma who underwent tumour excision or simple mastectomy 
as well as SLN biopsies. Patients with known distant metastatic 
disease were excluded from the study. All participating patients 
gave informed consent for the use of their clinical data and tissue 
specimens in this study. The Health Research Ethics Committee of 
Stellenbosch University approved the study (Ref. No. 513/10/216).
All the lymph nodes harvested were sectioned, embedded and 
examined in the same way as discussed below. Each formalin­fixed 
SLN was sectioned at 2 mm intervals along its long axis and was 
embedded in its entirety with the sectioned surface face down. 
Thorough cleaning of instruments and work surface area minimised 
the risk of mechanical transportation of carcinoma fragments. All 
sections were processed and embedded in paraffin wax according 
to routine histopathological techniques. Three sets of 15 consecutive 
serial sections, each measuring 3 ­ 5 µm in thickness and mounted 
on separate slides, were prepared from each case at one sitting, taking 
care to always use the same microtome in order not to lose any tissue 
in between sections. 
Each set of 15 consecutive sections was grouped into three levels, 
each comprising five serial sections. The first four sections were stained 
with H&E. The fifth section was stained for pancytokeratins, using 
MNF116. MNF116 labels epithelial tissues from simple glandular to 
stratified epithelium and is a useful tool for the identification of normal 
and neoplastic cells of epithelial origin. Monoclonal mouse antihuman 
cytokeratin, clone MNF116, Lot No. 69141 (Dakocytomation, 
Denmark) is provided in liquid form as cell culture supernatant 
dialysed against 0.05 mol/L Tris/HCl, pH 7.2, and contains 15 mmol/L 
NaN3. MNF116 is used at a dilution range of 1:100 and applied to 
formalin­fixed, paraffin­embedded sections of SLN, using 20 minutes’ 
heat­induced epitope retrieval. IHC staining was performed using the 
Leica Bond autostainer (Leica Biosystems, SA). 
In the absence of metastatic carcinoma in the first set of 15 
sections, the procedure was repeated on the second set of 15 sections 
and, if still negative for metastatic carcinoma, also on the third set 
of 15 sections. No further sectioning was done after the third set (45 
sections) in order to save costs and to avoid unnecessarily prolonged 
turnaround time of cases.
Metastatic carcinoma was distinguished from potential mimics 
including ectopic breast tissue, epithelial inclusions, displaced or 
transported tumour cells into lymph nodes and dendritic reticulum 
cells. 
Metastatic disease was reported according to criteria as specified by 
the World Health Organization (WHO).[8] Specifically, all metastases 
>2 mm in size were classified as macrometastases. A micrometastasis 
was diagnosed when one or more deposits of metastatic carcinoma 
were seen measuring >0.2 mm in size, but none of which was >2 mm. 
Isolated tumour cells were reported when single or small clusters of 
tumour cells were identified measuring not >0.2 mm in maximum 
dimension.
Design and method pertaining to data analysis and statistics
Data were collected in Excel (Microsoft, USA) and analysed using 
Statistica (version 11 of 2014, StatSoft, USA). Continuous data 
were described using means and standard deviations if normally 
distributed and medians and interquartile ranges if not normally 
distributed; 95% confidence intervals for the population mean 
were calculated. Categorical and ordinal data were described using 
frequency distributions. Data were presented graphically using either 
histograms or bar charts. A significance level of 5% was applied 
throughout. 
Results
Twenty patients who met the inclusion criteria of this study underwent 
SLN biopsies and simple mastectomies or tumour excisions. All the 
patients were female, with a mean age of 57 years (range 25 ­ 75 
years). Forty­four SLNs were available for analysis (mean 2.2 per 
patient, range 1 ­ 6). 
Twelve SLNs of eleven patients, varying in age between 34 and 72 
years, contained metastatic carcinoma, of which all were detected at 
level I. Ten patients had one positive lymph node each. One patient 
had two positive SLNs, the size of the metastatic tumour deposits 
measuring 5 × 4 mm and 2 × 2 mm. 
Nine cases showed macrometastases, varying in size between 
2 × 3.5 mm and 25 × 15 mm. One case showed micrometastases, 
measuring 0.08 × 0.08 mm in size, detected by MNF116 at level I, 
1/1 node involved by tumour (infiltrating carcinoma, of no specific 
type (NST), 47­year­old with breast tumour size of 20 × 20 mm) and 
one case showed isolated tumour cells, 1/1 node involved by tumour 
(infiltrating carcinoma, NST, 68­year­old with breast tumour size of 
40 × 25 mm). 
Eleven patients had metastatic carcinoma, with primary breast 
tumour sizes ranging between 40 × 25 mm and 10 × 10 mm. Ten of 
the patients underwent simple mastectomy and SLN biopsy and one 
patient underwent tumour excision and SLN biopsy. Six patients had 
infiltrating carcinoma, NST, and there was one patient each with the 
following tumour types: colloid carcinoma, medullary­like, classic 
lobular, tubulo­lobular and infiltrating papillary carcinoma.
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Tumour sections of three patients with infiltrating carcinoma, NST, 
revealed lymphovascular invasion. The breast tumour sizes of these 
cases measured 40 × 25 mm (1/1 node involved), 30 × 20 mm 
(1/3 nodes) and 15 × 12 mm (1/1 node), respectively. 
Nine patients (19 nodes in total, mean 2.1, range 1 ­ 5) did not 
have demonstrable metastatic disease in the 45 sections of levels 
I ­ IX, including MNF116 on every fifth section. These patients 
with negative SLNs ranged in age between 29 and 68 years and had 
breast tumour sizes ranging between 30 × 30 mm and 10 × 10 mm. 
Of these patients with negative SLNs, five patients underwent simple 
mastectomies and SLN biopsies and four patients underwent tumour 
excision and SLN biopsy. Five patients had infiltrating carcinoma, 
NST, and one patient had infiltrating duct carcinoma with apocrine 
differentiation. 
Five of the 11 patients (82%) with metastatic tumour received 
neo­adjuvant chemotherapy prior to SLN biopsy. Their nodal status 
ranged from 1/1, 1/3 and 1/4 nodes involved by metastatic tumour. 
Six of the nine patients (66%) without metastatic tumour received 
neo­adjuvant chemotherapy. Three had complete tumour response 
with nodal status of 0/4, 0/2 and 0/5 nodes involved by metastatic 
tumour, respectively.
Statistical analysis of data confirmed that the cases with metastatic 
tumour did not share predictive characteristics. The smallest breast 
tumour (medullary­like type) that showed metastatic disease on H&E 
staining was 10 × 10 mm in size, whereas two tumours (infiltrating duct 
carcinoma, NST) which did not show metastatic disease, also measured 
10 × 10 mm in size each. One tumour (infiltrating duct carcinoma, 
NST) without metastatic disease, measured 30 × 26 mm in size. 
Discussion
SLN biopsy is rapidly emerging as an alternative to axillary lymph 
node dissection in staging the axilla in patients with early breast 
cancer.[7] SLN biopsy has been incorporated into the ASCO guideline; 
however, the optimal histopathological work­up of SLNs is currently 
not standardised.[7]
Klevesath et al.[1] prepared SLNs by cutting them in 2 mm slices 
longitudinally and found that 56/216 patients (25.9%) showed 
metastatic tumour on H&E only. A further 9 patients (4.2%) had 
metastatic deposits detected by IHC, of whom 4 (2.0% of total, 44.4% 
of those detected by IHC) had micrometastatic disease, ranging from 
0.2 mm to 1.0 mm in size. Similar to the findings of Klevesath et al.,[1] 
this study demonstrated that all the positive SLNs were detected at 
level I (4 H&E stains and one MNF116 IHC stain). All the SLNs that 
were negative at level I remained negative in subsequent levels II ­ IX. 
Weaver[6] recommended that nodes be sectioned at 2 mm intervals 
and found that all metastases larger than 2.0 mm were detected 
by examination of one section from the surface of the block. They 
acknowledged that more comprehensive sampling would identify 
additional micrometastases and isolated tumour cells even though 
their prognostic significance is still unclear. 
Lyman et al.[7] recommended that nodes be cut into longitudinal 
slices no thicker than 2 mm and that at a minimum, full cross­
sections of each SLN slice should be prepared and examined with 
H&E staining. They stated that additional micrometastases were 
more likely to be detected with step sections at 200 ­ 500 µm intervals 
than with superficial serial sections alone. 
In this study, lymph nodes were sectioned at 2 mm intervals 
longitudinally and with serial sectioning, metastatic disease was 
detected within the first four H&E­stained sections in 9/11 cases. The 
single case that required MNF116 IHC staining to confirm metastatic 
disease comprised infiltrating duct carcinoma, NST (metastatic 
tumour size: 0.8 × 0.8 mm; micrometastases). 
Based on the results of this study, a cost­effective approach to 
the assessment of SLNs in breast carcinoma should include the 
histopathological evaluation of four H&E­stained sections, which 
will detect the overwhelming majority of metastatic carcinoma. If 
metastatic carcinoma is absent, one IHC stain should be performed 
for pancytokeratins (such as MNF116), to aid in the detection 
of possible small foci of metastatic carcinoma. In addition to 
the high detection rate of metastatic carcinoma, this approach 
is always cost effective, especially in a resource­limited setting. 
During the course of this study one H&E section cost R63.68 in the 
public sector and R85.80 in the private sector, while one MNF116 
immunohistochemistry stain cost R384.86 in the public sector and 
R512.10 in the private sector, exclusive of VAT. 
Owing to limited resources, this was a very small study, running 
over a 3­month period. Despite the small cohort of patients in this 
study, all specimens were handled optimally, without confounding 
technical or administrative errors.
Conclusion
The results obtained in this study justify a larger study with more 
patients to verify the findings and to determine potentially significant 
statistical influence on patient outcome. 
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